Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.51 |
| ▸ | P4HB | P07237 | 4/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729435 | 0.90 | MAOB (0.47) | MAOBP4HBCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3735487 | 0.86 | MAOB (0.51) | MAOBP4HBCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL2646518 | 0.83 | MAOB (0.64) | MAOBP4HBCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3743383 | 0.82 | MAOB (0.64) | MAOBP4HBCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL25203590 | 0.81 | P4HB (0.70) | MAOBP4HBCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3736318 | 0.76 | LMNA (0.50) | CYP1A1CYP1B1CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL3729438 | 0.76 | NPC1 (0.50) | MAOBP4HBCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3734079 | 0.76 | CYP1A1 (0.47) | MAOBP4HBCYP1A1CYP1B1MAOA | |
| SCHEMBL3748001 | 0.76 | ABCG2 (0.66) | CYP1A1CYP1B1CYP1A2CYP2D6CYP3A4 | |
| SCHEMBL9071497 | 0.75 | MAOB (0.57) | MAOBP4HBCYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | MAOB 716/4885P4HB 4731/4885CYP1A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.